H.C. Wainwright initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $13 price target TuHURA is a clinical-stage biotechnology company that is advancing targeted therapeutics to address areas of serious unmet need within oncology, spanning liquid and solid tumors, the analyst tells investors in a research note. The firm says the company’s IFx-2.0 has demonstrated a “highly encouraging” overall response rate in Phase 1b.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.